| |
| Device | FoundationOne CDx (F1CDx) |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Foundation Medicine, Inc. 400 Summer St. Boston, MA 02210 |
| PMA Number | P170019 |
| Supplement Number | S021 |
| Date Received | 10/29/2020 |
| Decision Date | 05/28/2021 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT02150967
|
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for FGFR2 fusion/rearrangements in patients with Cholangiocarcinoma who may benefit from treatment with Truseltiq (infigratinib). |